iBio uses the FastPharming System to quickly produce biotherapeutic and vaccine candidates for unmet medical needs.
In the area of human disease, IBIO-100 targets fibrosis, a leading cause of organ failure worldwide. IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak. IBIO-201 is a vaccine targeting COVID-19 that uses iBio's patented LicKM platform .
Additionally, iBio is developing a candidate vaccine for classical swine fever, an agricultural disease so severe that infected pig herds are destroyed to prevent spread. The IBIO-400 program has demonstrated complete protection in live-virus challenge studies while providing an ability to discriminate between infected and vaccinated animals (DIVA).